Significance of carcinoembryonic antigen in retinoblastoma

ARUP DAS,1 INDRA SEKHAR ROY,1 TUSHAR K. MAITRA,2 AND ASHISH KANJILAL2

From the 1Regional Institute of Ophthalmology, Calcutta, and 2Kothari Centre of Gastroenterology, Calcutta, India

SUMMARY The role of estimating the serum carcinoembryonic antigen (CEA) in the diagnosis and prognosis of retinoblastoma cases has been evaluated. Although the mean serum CEA titre in children with retinoblastoma was higher than that in control children (p=0.01), the serum CEA level itself was found not to be a useful marker in the diagnosis of retinoblastoma. A significant correlation of serum CEA titre with progression or regression of the disease observed during therapy in most cases indicated that serial assays of serum CEA may be important in the follow-up of cases with retinoblastoma. The lower CEA values in aqueous humour and subretinal fluid from eyes with retinoblastoma than in the serum suggests that the tumour does not secrete the CEA.

The detection of tumour-associated antigens in serum or body fluids has been the subject of recent interest in the diagnosis and follow-up of malignant tumours.1 Elevated serum levels of one of these antigens, carcinoembryonic antigen (CEA), have been described in many malignant conditions,1,2 especially colorectal and pancreatic carcinomas, and also recently in many nonmalignant conditions.1 So far only a few studies have emphasised the role of CEA in retinoblastoma.3-4

In the present study we aimed to find out the usefulness of measuring the serum CEA level in the diagnosis and prognosis of retinoblastoma cases.

Materials and methods

Twelve cases of histologically proved retinoblastoma (age range 1 year 5 months to 5 years 2 months) seen at the Regional Institute of Ophthalmology, Calcutta, were included in this study. The diagnosis of retinoblastoma was made on the basis of clinical history, ocular and systemic examination, slit-lamp biomicroscopy, ophthalmoscopy, and radiography of the skull and orbits, together with estimation of lactate dehydrogenase (LDH) and the electrophoretic protein pattern of the aqueous in cases where aqueous collection was possible from the intact anterior chamber. All these cases underwent enucleation or exenteration, and the eyeballs were subjected to histopathological examination for the confirmation of diagnosis. After operation the patients were treated with radiotherapy or chemotherapy or both depending on the histopathological extent of the tumour and assessment of any developing metastatic nodules. Cases were followed up for every month for a period of 6 months. In 3 cases gamma scan for detection of bony metastases was performed.

In 11 of these patients the serum CEA levels were estimated before enucleation or exenteration and 2 weeks after and then at intervals in selected cases. In one case no pre-enucleation value for serum CEA was available.

The sera from 10 children (age range 1 to 5 years) with congenital cataract (6), Coats's disease (2), endophthalmitis (1), and retinal detachment (1) were also collected for control serum CEA values. In selecting the control children diseases that come into the differential diagnosis of retinoblastoma were included, as this was considered to be a better control population than age-matched normal children (Felberg, personal communication, 1982).

The sera samples were stored at −20°C, and CEA levels were measured with a radioimmunoassay kit (Phadebas CEA PRIST, Pharmacia Diagnostics). Counting was done on a Beckman Gamma Counter (model Gamma 4000).

In addition, from 4 patients with retinoblastoma the pre-enucleation sera and aqueous specimens from
Carcinoembryonic antigen

The enucleated eyeballs were also subjected to CEA assay. In 2 of these 4 eyes the subretinal fluid (SRF) was collected by paracentesis of the intact globe for CEA estimation. Aqueous humour and subretinal fluid samples were obtained with a 25-gauge needle attached to a dry tuberculin syringe. These samples were stored and processed in the same way as the serum samples.

Results

The mean serum CEA titre in children with retinoblastoma (7·5 µg/l) was higher than the mean serum CEA titre in control children (2·77 µg/l) (Table 1). While 55-5% of the retinoblastoma cases had serum CEA levels more than 5·0 µg/l, none of the control children showed serum CEA levels above 5·0 µg/l.

In 5 (cases 1 to 5) out of 12 children the serum CEA titre dropped significantly 2 weeks after surgery, and no recurrence of metastasis was noted within 6 months in them except in one case (case 3) (Table 2). This group included 2 cases with histological evidence of optic nerve invasion, and both needed postoperative radiotherapy. In the other 6 cases (cases 6 to 11) the CEA titre continued to rise even after surgery, and these mostly included children with proptosis and metastases. The spread of the disease was reflected in the immediate rise of the postoperative serum CEA values (Table 2).

In case 7 the serum CEA level continued to rise even after surgery and chemotherapy, and the child

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Total no. of children</th>
<th>No. of cases</th>
<th>Mean CEA titre µg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinoblastoma</td>
<td>11</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Control children</td>
<td>10</td>
<td>5</td>
<td>—</td>
</tr>
</tbody>
</table>

*SD=5·106; n=11.
†Congenital cataract (6), Coats’s disease (2), endophthalmitis (1), retinal detachment (1). SD=1·084; n=10.

Table 2 Change in serum CEA values in retinoblastoma patients after therapy (surgical, radio-, or chemotherapy)

<table>
<thead>
<tr>
<th>No.</th>
<th>Serum CEA (µg/l)</th>
<th>Nature of postoperative therapy</th>
<th>Serum CEA (µg/l)</th>
<th>Remarks</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Preoperative</td>
<td>Postoperative (after 2 weeks of surgery)</td>
<td>Postradio-chemotherapy after 6 weeks</td>
<td>after 12 weeks</td>
</tr>
<tr>
<td>1</td>
<td>8·60</td>
<td>7·80</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>2</td>
<td>9·20</td>
<td>4·50</td>
<td>Radio-</td>
<td>—</td>
</tr>
<tr>
<td>3</td>
<td>12·20</td>
<td>6·0</td>
<td>Radio-</td>
<td>7·80</td>
</tr>
<tr>
<td>4</td>
<td>11·80</td>
<td>4·20</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>5</td>
<td>14·30</td>
<td>9·30</td>
<td>—</td>
<td>—</td>
</tr>
<tr>
<td>6</td>
<td>14·0</td>
<td>16·50</td>
<td>Radio-</td>
<td>6·0</td>
</tr>
<tr>
<td>7</td>
<td>1·60</td>
<td>3·0</td>
<td>Chemo-</td>
<td>4·0</td>
</tr>
<tr>
<td>8</td>
<td>2·60</td>
<td>4·82</td>
<td>Chemo-</td>
<td>2·05</td>
</tr>
<tr>
<td>9</td>
<td>2·45</td>
<td>4·80</td>
<td>Chemo-</td>
<td>4·48</td>
</tr>
<tr>
<td>10</td>
<td>3·60</td>
<td>4·00</td>
<td>Radio-</td>
<td>—</td>
</tr>
<tr>
<td>11</td>
<td>2·20</td>
<td>9·10</td>
<td>Radio- and chemo-</td>
<td>—</td>
</tr>
<tr>
<td>12</td>
<td>Not done</td>
<td>2·40</td>
<td>Radio- and chemo-</td>
<td>4·80</td>
</tr>
</tbody>
</table>

Leucocoria; no optic nerve infiltration; no recurrence or metastases within 6 months
Leucocoria; optic nerve infiltration; no recurrence or metastases within 6 months
Proptosis; optic nerve infiltration; metastases appeared within 3 months
Leucocoria; no optic nerve infiltration; no recurrence or metastases within 6 months
Leucocoria; no optic nerve infiltration; no recurrence or metastases within 6 months
Leucocoria; optic nerve infiltration; no recurrence or metastases within 6 months
Massive proptosis; optic nerve infiltration; died within 3 months of exenteration
Proptosis; optic nerve infiltration; metastases present; all metastases disappeared at the end of chemotherapy within 3 months
Proptosis; optic nerve infiltration; metastases present; with chemotherapy metastases first disappeared and again recurred after 4 months
Proptosis; optic nerve infiltration; metastases appeared within 2 months
Proptosis; optic nerve infiltration; metastases appeared within 3 months
Recurrent in the same orbit occurred within 2 months of surgery in spite of radiotherapy

Table 1 Serum CEA values in retinoblastoma children and control children

<table>
<thead>
<tr>
<th>Diagnosis</th>
<th>Total no. of children</th>
<th>0·2-5 µg/l</th>
<th>2·6-5·0 µg/l</th>
<th>5·1-10·0 µg/l</th>
<th>&gt;10·0 µg/l</th>
<th>Mean CEA titre µg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>Retinoblastoma</td>
<td>11</td>
<td>3</td>
<td>2</td>
<td>2</td>
<td>4</td>
<td>7·5*</td>
</tr>
<tr>
<td>Control children</td>
<td>10</td>
<td>5</td>
<td>5</td>
<td>—</td>
<td>—</td>
<td>2·77†</td>
</tr>
</tbody>
</table>

*SD=5·106; n=11.
†Congenital cataract (6), Coats’s disease (2), endophthalmitis (1), retinal detachment (1). SD=1·084; n=10.
Table 3  Comparison of CEA values in serum and ocular fluids

<table>
<thead>
<tr>
<th>Serial no.</th>
<th>Serum CEA μg/l</th>
<th>Aqueous humour CEA μg/l</th>
<th>Subretinal fluid CEA μg/l</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>3.10</td>
<td>1.50</td>
<td>2.20</td>
</tr>
<tr>
<td>2</td>
<td>7.00</td>
<td>5.20</td>
<td>5.80</td>
</tr>
<tr>
<td>3</td>
<td>9.00</td>
<td>1.00</td>
<td>—</td>
</tr>
<tr>
<td>4</td>
<td>11.0</td>
<td>2.05</td>
<td>—</td>
</tr>
</tbody>
</table>

died in 3 months. In case 8, although the CEA titre was elevated after surgery, it came down after chemotherapy, with the concurrent disappearance of metastases. In case 9 the CEA level increased after removal of the tumour but with chemotherapy, when metastases were found to disappear, there was no further rise in the CEA titre. After 4 months, when metastases again developed, there was concurrent elevation of the CEA titre. In case 12 no preoperative value for serum CEA was available, as the case was referred to us after enucleation, and when orbital recurrence occurred despite radiotherapy there was also a rise in the serum CEA titre (Table 2).

As shown in Table 3, the CA values for serum were higher than those for intraocular fluids in the small group of cases in which they were compared. The concentrations of CA in 2 samples of subretinal fluid were almost similar to the aqueous CA levels.

Discussion

Though in comparison with the control children the retinoblastoma cases showed a significantly higher (p=0.01) mean serum CEA value, the individual serum CEA values in 44-5% of the children with retinoblastoma overlapped the individual CA values of the control children. Therefore the serum CEA level itself was not a significant diagnostic marker for retinoblastoma. Michelson et al.3 have made a similar observation. This limitation of the diagnostic value of the serum CEA may not be unique for retinoblastoma, since other investigators have also observed that some of the diagnosed malignant neoplastic conditions might be associated with normal serum CA values.1-6

A decrease of the serum CEA titre following surgery indicates a good prognosis, as the incidence of recurrence or metastasis is low in such cases. A similar fall of the serum CEA level after surgery in other malignant conditions has been ascribed to the decrease in the tumour burden.7 However, the source of CEA is retinoblastoma is probably not the tumour,8 and so the concept of decrease in the tumour burden may not be applicable. Most of the cases in which the postoperative level of serum CEA was higher than the preoperative value developed metastasis or tumour recurrence, so that this condition indicated an unfavourable prognosis. The response with radio- or chemotherapy, if any, was also reflected in a decrease in the serum CEA level, and, if the tumour recurred after therapy, the serum CEA titre also went up. Thus from an increase in the titre of serum CEA following surgery or radio- and/or chemotherapy one can detect cases with an unfavourable prognosis. Serial serum CA assays during therapy may help in the management of retinoblastoma cases.

The lower CA values in SRF and aqueous compared with the serum in the present series precludes the possibility of the tumour as the source of CEA. If the CA were secreted by the tumour, it would be released into the surrounding subretinal fluid and then to aqueous, and this would lead to higher CA levels in SRF and aqueous than in the serum. Moreover by immunohistochemical techniques CA could be demonstrated neither in the tumour tissue nor in culture media of the retinoblastoma tumour tissue.9

Although, apparently, CEA may not be produced by the tumour, it is possible that the release of a chemical mediator from the tumour may diffuse into the circulation and so stimulate the synthesis of CEA in other target organs.3 Even with this possibility, the tumour bulk may be controlling the synthesis of CEA indirectly through the controlled production of the chemical mediator.

We thank Dr K. N. Jalan, chief co-ordinator, Kothari Centre of Gastroenterology, Calcutta, for his kind help, and Mr E. G. P. Nair for secretarial assistance.

References

Significance of carcinoembryonic antigen in retinoblastoma.

A Das, I S Roy, T K Maitra and A Kanjilal

doi: 10.1136/bjo.68.4.252

Updated information and services can be found at:
http://bjo.bmj.com/content/68/4/252

Email alerting service

Receive free email alerts when new articles cite this article.
Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/